Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-13 4:10 pm Purchase | 2023-02-03 | 13G | Avalo Therapeutics, Inc. AVTX | Great Point Partners, LLC | 4,061 7.120% | 4,061 (New Position) | Filing History |
| 2023-02-09 4:27 pm Purchase | 2023-02-07 | 13D | Avalo Therapeutics, Inc. AVTX | Armistice Capital, LLC | 19,928 35.400% | 1,876 (+10.39%) | Filing History |
| 2022-08-11 4:09 pm Sale | 2022-08-08 | 13D | Avalo Therapeutics, Inc. AVTX | Armistice Capital, LLC | 18,052 44.400% | -0 (-0.00%) | Filing History |
| 2022-08-08 07:23 am Purchase | 2022-07-25 | 13G | Avalo Therapeutics, Inc. AVTX | Caissa Capital Management ltd. | 4,086 10.430% | 1,968 (+92.90%) | Filing History |
| 2022-05-17 3:45 pm Purchase | 2022-05-04 | 13G | Avalo Therapeutics, Inc. AVTX | Caissa Capital Management ltd. | 2,118 5.410% | 2,118 (New Position) | Filing History |
| 2022-03-15 5:16 pm Purchase | 2022-03-14 | 13D | Avalo Therapeutics, Inc. AVTX | Armistice Capital, LLC | 18,052 44.500% | 408 (+2.31%) | Filing History |
| 2022-02-14 4:29 pm Purchase | 2021-12-31 | 13G | Avalo Therapeutics, Inc. AVTX | Point72 Asset Management, L.P. | 2,088 5.400% | 1 (+0.05%) | Filing History |
| 2022-02-14 08:07 am Purchase | 2021-12-31 | 13G | Avalo Therapeutics, Inc. AVTX | Nantahala Capital Management, LLC | 2,956 7.500% | 2,956 (New Position) | Filing History |
| 2022-01-19 6:41 pm Purchase | 2022-01-18 | 13D | Avalo Therapeutics, Inc. AVTX | Armistice Capital, LLC | 17,643 43.700% | 486 (+2.83%) | Filing History |
| 2021-12-16 4:04 pm Unchanged | 2021-12-14 | 13D | Avalo Therapeutics, Inc. AVTX | Armistice Capital, LLC | 17,157 42.500% | 0 (Unchanged) | Filing History |
| 2021-11-08 4:05 pm Unchanged | 2021-11-04 | 13D | Avalo Therapeutics, Inc. AVTX | Armistice Capital, LLC | 17,157 43.900% | 0 (Unchanged) | Filing History |
| 2021-10-14 9:01 pm Purchase | 2021-10-14 | 13D | Avalo Therapeutics, Inc. AVTX | Armistice Capital, LLC | 17,157 43.900% | 143 (+0.84%) | Filing History |
| 2021-09-21 4:51 pm Purchase | 2021-09-17 | 13G | Avalo Therapeutics, Inc. AVTX | Point72 Asset Management, L.P. | 2,087 5.400% | 2,087 (New Position) | Filing History |
| 2021-09-17 3:04 pm Purchase | 2021-09-17 | 13D | Avalo Therapeutics, Inc. AVTX | Armistice Capital, LLC | 17,014 43.900% | 17,014 (New Position) | Filing History |
| 2021-02-16 06:23 am Purchase | 2020-12-31 | 13G | Cerecor Inc. CERC | Nantahala Capital Management, LLC | 6,233,316 8.300% | 6,233,316 (New Position) | Filing History |